Navigation Links
Jubilant Enters Research Collaboration With AstraZeneca
Date:5/5/2009

ation complements our internal capabilities and increases the capacity of our pre-clinical programs. It is a concrete example of the innovative approaches we are taking to deliver a sustainable Discovery pipeline with a lean and agile organization. Ultimately, this will provide us with more shots on goal as we look to sustain a competitive portfolio and provide meaningful medicines to patients."

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: http://www.astrazeneca.com

About Jubilant Biosys

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd.,provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 300 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharma chem, molecular modeling, crystallography and information technology supporting discovery efforts.

For more information please visit: http://www.jubilantbiosys.com

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The
'/>"/>

SOURCE Jubilant Organosys Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
2. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
3. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
4. Another LNA-based RNA Inhibitor Enters Clinical Trials
5. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
6. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
7. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
8. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
9. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
10. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
11. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Mass. , July 29, 2014  Instrumentation Laboratory (IL) ... including a new corporate logo. This is part of a ... Founded in Boston, MA , ... family of companies since 1992.  Other companies in the group ... Biokit and Systelab ( Barcelona, Spain ).  Like ...
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
(Date:7/29/2014)... LAKE CITY , July 29, 2014  The ... The Grand American Hotel in Salt Lake ... speakers representing some of most respected healthcare organizations in ... Health Catalyst , is an industry conference devoted to ... healthcare analytics,  an essential element of both accountable care ...
Breaking Medicine Technology:Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 The ... Gossip reveals the inside story to Gary M. Levin’s ... a remarkable cure method for this serious disorder. Levin ... most discouraging conditions that can be found in patients. ... MD and surgeon. For many years, Levin has worked ...
(Date:7/29/2014)... Winter is here down under, and ... Sydney’s central business district. That is, until a troop ... the otherwise ordinary day into a celebration—a celebration of ... advocates of The Truth About Drugs, a drug prevention ... They woke up the city with a rousing performance ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip reveals ... 5 step holistic system that will permanently eliminate all the ... Coleman his natural treatment will banish symptoms such as mild ... beeping sound heard by patients will be gone forever. , ... 60 days. The author of this program says that at ...
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) --,The time at ... affect their chances for survival, new research suggests. ... weekends or during holidays is associated with a 13 ... business hours, researchers report. Every year, more than ... most severe type of heart attack, which is caused ...
(Date:7/29/2014)... the bite of a brown recluse spider is poisonous, ... expert notes. It,s still important to recognize the ... recluse spider bite, warned Dr. Donna Seger, medical director ... dangerous bites are on the rise. "As physicians, ... [bite] has classic characteristics, but if physicians are not ...
Breaking Medicine News(10 mins):Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2
... Aeras and the China National Biotech Group (CNBG) today ... organizations to pursue opportunities to jointly develop tuberculosis (TB) vaccines ... The partnership is intended to leverage both organizations, capabilities ... a major public health priority in China, where there are ...
... Serena Gordon HealthDay Reporter , MONDAY, July 25 (HealthDay ... worry to add to their list: Kids younger than 10 years ... on their own. New research found that while children ... the street solo -- they do stop and look both ways ...
... specific genes shuts down the mass production of antibodies launched ... by scientists at The University of Texas MD Anderson Cancer ... "Regulatory T cells prevent unwanted or exaggerated immune system ... been unclear," said paper senior author Chen Dong, Ph.D., professor ...
... ALBUQUERQUE, N.M. Americans are used to drinking from ... water utilities might be vulnerable to terrorist attacks or ... an open-source software developed by Sandia National Laboratories ... public water systems can be protected through enhanced detection ...
... , MONDAY, July 25 (HealthDay News) -- As ... school this fall, the American Lung Association urged parents to ... and help ease their transition back to the classroom. ... back-to-school necessities, it is even more essential for parents of ...
... of oncologists in the Program in Women,s Oncology at Women ... guide to the human papilloma virus (HPV) so physicians can ... women with the virus. Dx/Rx: Human Papilloma Virus was ... oncology at Women & Infants and associate professor of obstetrics ...
Cached Medicine News:Health News:Aeras and China National Biotech Group sign memorandum of understanding for TB vaccine R&D 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 3Health News:Specialized regulatory T cell stifles antibody production centers 2Health News:Specialized regulatory T cell stifles antibody production centers 3Health News:Sandia's CANARY software protects water utilities from terrorist attacks and contaminants 2Health News:Sandia's CANARY software protects water utilities from terrorist attacks and contaminants 3Health News:Preparation Key When Kids With Asthma Go Back to School 2Health News:Oncologists publish HPV manual for physicians 2
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... quadripolar pacing wire design offers ... sensing in the atrium and ... wires in one lead design. ... and ventricle are color-coded for ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: